

JULY 22, 2020 IMMEDIATE ACTION

Update Notes

Due to federal regulatory requirements, revisions to the Warde in-house tests include the required AOE prompt questions. Requirements for State Health Reporting also include patient demographics and ordering physician address, phone number and NPI. Please check that this information is being sent to Warde electronically in the HL7 message for all COVID-19 and non-COVID-19 State health reportable diseases.

Update Summary		
Update Existing Test	7/27/2020	AFOGA - " Anti-Fodrin Antibody, IgG, IgA RDL"
Update Existing Test	7/28/2020	NMH24 - "N-Methylhistamine, 24 Hour, Urine"
Update Existing Test	7/27/2020	PMSCQ - " Anti-PM/Scl-100 Ab RDL"
Inactivate Test With Replacement	7/28/2020	COV2G - "SARS Coronavirus 2 IgG Antibody" replaced by COVG - "SARS Coronavirus 2 IgG Antibody"
Inactivate Test With Replacement	7/28/2020	COVWD - "SARS-COV-2 Qualitative" replaced by COVW - "SARS-COV-2 Qualitative"
Inactivate Test With Replacement	7/28/2020	NICKU - "Nickel, Urine" replaced by NICRU - "Nickel, Urine"
Inactivate Test Without Replacement	8/3/2020	CANAG - "Candida Antigen"

Update Existing Test					
Effective Date	7,	/27/2020			
Name	Alpha-Fo	drin Ab IgG, IgA			
Code		AFOGA			
Interface Order Code	3	3721100			
Legacy Code	AF	AFODGASP			
Notes	The test name and the nam	e of the compone	ents has changed.		
Required Testing C	hanges				
Name	Anti-Fodrin Aı	ntibody, IgG, IgA	RDL		
Result Code	Name	LOINC Code	AOE/Prompt ²		
3721120	Anti-Fodrin Ab, IgG (RDL)	Not available	No		
3721140	Anti-Fodrin Ab, IgA (RDL)	Not available	No		

Update Existing	Update Existing Test					
Effective Date	7/28/2020					
Name	N-Methylhistamine, 24 Hour, Urine					
Code	NMH24					
Interface Order Code	3800110					
Legacy Code	NMH24					
Notes	Stability changes					
Required Testing Changes						
Stability	Room temperature: 14 days; Refrigerated: 28 days; Frozen: 28 days					

LAST EDITED: 2020-07-22 PAGE 1 OF 8



JULY 22, 2020 IMMEDIATE ACTION

Update Existing Test						
Effective Date	7,	/27/2020				
Name	Anti-PM,	/Scl-100 Ab (EIA)				
Code		PMSCQ				
Interface Order Code	:	3423685				
Legacy Code		PMSCQ				
Notes	The test name and cor	nponent name ha	ave changed.			
Required Testing C	hanges					
Name	Anti-PM	Anti-PM/Scl-100 Ab RDL				
Reference Range	Negative: <20					
Result Code	Name	LOINC Code	AOE/Prompt ²			
3423685	Anti-PM/Scl-100 Ab (RDL)	81732-0	No			

LAST EDITED: 2020-07-22 PAGE 2 OF 8



JULY 22, 2020 IMMEDIATE ACTION

Inactivate Test	With Replacement			
Effective Date	7,	28/2020		
	Inactivated Te	st		
Name	SARS Corona	virus 2 IgG Antibo	dy	
Code		COV2G		
Legacy Code ¹		COV2G		
Interface Order Code	3	000068		
Notes				
	Replacement To	est		
Name	SARS Corona	virus 2 IgG Antibo	dy	
Code		COVG		
CPT Code(s)	86769			
CF1 Code(s)				
Notes				
Specimen Requirer	nents			
	Draw blood in a SST. Centrifuge, remove s	erum from cells	and send 0.5 mL serum (0.3 mL	
Specimen Required	minimum) refrigerated in a screw-capped		·	
	Serum: Red-top			
Alternate Specimen	Plasma: Sodium or lithium heparin, EDTA			
	·			
Rejection Criteria	Gross hemolysis, lipemia			
Rejection Criteria				
Stability	Room temperature: 8 hours; Refrigerated	7 days; Frozen:	14 days	
Stability				
Performing Information	ation			
Methodology	Chemilumines	cence Immunoas	say	
Reference Range	Negative	:: <15.0 AU/mL		
Reference Range	Positive:	>=15.0 AU/mL		
Performed Days	Sunday-Friday			
renomieu Days				
Turnaround Time	48 hours			
Performing Laboratory				
Interface Informati	on			
Legacy Code ¹		COVG		
Interface Order Code		000226		
Result Code	Name	LOINC Code	AOE/Prompt ²	
	First Test? (Y/N/U)			
3000227	Acceptable Prompt Responses:	95417-2	Yes	
3000227	Y N	33417-Z	ies	
	U			

LAST EDITED: 2020-07-22 PAGE 3 OF 8



JULY 22, 2020 IMMEDIATE ACTION

3000228	Employed in healthcare? (Y/N/U) Acceptable Prompt Responses: Y N U	95418-0	Yes
3000229	Symptomatic as defined by CDC? (Y/N/U) Acceptable Prompt Responses: Y N U	95419-8	Yes
3000231	If yes, then Date of Symptom Onset mm/dd/yy Acceptable Prompt Responses: If applicable: mm/dd/yy If not applicable: NA or N/A	11368-8	Yes
3000233	Hospitalized? (Y/N/U) Acceptable Prompt Responses: Y N U	77974-4	Yes
3000237	ICU? (Y/N/U) Acceptable Prompt Responses: Y N U	95420-6	Yes
3000239	Resident in a congregate care setting? (Y/N/U) Acceptable Prompt Responses: Y N U	95421-4	Yes
3000241	Pregnant? (Y/N/U) Acceptable Prompt Responses: Y N U	82810-3	Yes
3000242	SARS Coronavirus 2 IgG Ab	Not available	No
3000243	SARS Coronavirus 2 IgG Ab Interpretation	94563-4	No

LAST EDITED: 2020-07-22 PAGE 4 OF 8



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

	Immunology	1				
	Collected: 07	/20/202	0 15:00	Received	1: 07/22/2020	17:01
<u>Test Name</u>	Result	Flag	Ref-Ranges	<u> </u>	<u>Units</u>	<u>Site</u>
SARS Coronavirus 2 lgG Antibody						
First Test? (Y/N/U)	Υ					WMRL
Employed in healthcare? (Y/N/U)	Υ					WMRL
Symptomatic as defined by CDC? (Y/N/U)	Υ					WMRL
If yes, then Date of Symptom Onset mm/dd/yy	07/01/20					WMRL
Hospitalized? (Y/N/U)	N					WMRL
ICU? (Y/N/U)	N					WMRL
Resident in a congregate care setting? (Y/N/U)	N					WMRL
Pregnant? (Y/N/U)	N					WMRL
SARS Coronavirus 2 IgG Ab	<3.80		<15.00		AU/mL	WMRL
SARS Coronavirus 2 IgG Ab Interpretation	Negative		Negative			WMRL

SARS-CoV-2 IgG antibodies were not detected.

Please note that this does not rule out prior infection with SARS-CoV-2, as negative results may occur in serum collected too soon following infection, in immunosuppressed patients, or in some individuals with prior mild illness. Sensitivity of the assay may be negatively affected if testing is performed less than 15 days after initial diagnosis. This test should NOT be used to diagnose or to exclude active or recent COVID-19. Molecular (PCR) testing is recommended to establish a diagnosis of COVID-19 in symptomatic patients. This test was performed on the Diasorin Liaison analysis platform and is authorized by FDA for use under an emergency use authorization (EUA). Analytical performance characteristics were validated by the manufacturer and by Warde Medical Laboratory in a manner consistent with CLIA requirements.

The FDA requires that a fact sheet be made available for patients and healthcare providers regarding this test.

The fact sheet for patients may be found at http://www.wardelab.com/Diasorin_SARSCoV2_antibody_fact_sheet_for_patients.pdf

The fact sheet for healthcare providers may be found at http://www.wardelab.com/Diasorin_SARSCoV2_antibody_fact_sheet for health care providers.pdf

Performing Site

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, $\,$. - NOT TESTED

B522000014 WX0000003039 Printed D&T: 07/22/20 17:02 Ordered By: CLIENT CLIENT WX00000000001595

William G. Finn, M.D. - Medical Director Form: MM RL1 PAGE 1 OF 1



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

	lmmun	ology				
	Colle	cted: 07/21/2020	08:30	Received:	07/22/2020	16:59
<u>Test Name</u>	Result	<u>Flag</u>	Ref-Ranges		<u>Units</u>	<u>Site</u>
SARS Coronavirus 2 IgG Antibody						
First Test? (Y/N/U)	Υ					WMRL
Employed in healthcare? (Y/N/U)	U					WMRL
Symptomatic as defined by CDC? (Y/N/U)	N					WMRL
If yes, then Date of Symptom Onset mm/dd/yy	NA					WMRL
Hospitalized? (Y/N/U)	N					WMRL
ICU? (Y/N/U)	N					WMRL
Resident in a congregate care setting? (Y/N/U)	N					WMRL
Pregnant? (Y/N/U)	N					WMRL
SARS Coronavirus 2 IgG Ab	89.00	Н	<15.00		AU/mL	WMRL
SARS Coronavirus 2 IgG Ab Interpretation	Positive	AB	Negative			WMRL

SARS-CoV-2 IgG antibodies were detected. Results suggest recent or prior infection with SARS-CoV-2.

This test was performed on the Diasorin Liaison analysis platform and is authorized by FDA for use under an emergency use authorization (EUA). Analytical performance characteristics were validated by the manufacturer and by Warde Medical Laboratory in a manner consistent with CLIA requirements. This test should NOT be used for primary diagnosis of COVID-19 or SARS-CoV-2 infection. Furthermore, the relationship between detectable antibody via qualitative assay and protective immunity has NOT been established, and no inference should be made on presumed immunity to infection based on this result.

The FDA requires that a fact sheet be made available for patients and healthcare providers regarding this test.

The fact sheet for patients may be found at http://www.wardelab.com/Diasorin_SARSCoV2_antibody_fact_sheet_for_patients.pdf

The fact sheet for healthcare providers may be found at http://www.wardelab.com/Diasorin_SARSCoV2_antibody_fact_sheet_for_health_care_providers.pdf

Performing Site:

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, $\,$. - NOT TESTED

B522000013 WX0000003039 Printed D&T: 07/22/20 17:00 Ordered By: CLIENT CLIENT WX00000000001595

William G. Finn, M.D. - Medical Director Form: MM RL1 PAGE 1 OF 1



JULY 22, 2020 IMMEDIATE ACTION

Inactivate Test	Inactivate Test With Replacement					
Effective Date	7/	28/2020				
	Inactivated Test					
Name	SARS-CO	V-2 Qualitative				
Code	(COVWD				
Legacy Code ¹		COVWD				
Interface Order Code	3	000065				
Notes						
	Replacement Te	est				
Name	SARS-Co	V-2 Qualitative				
Code		COVW				
CPT Code(s)	U0003					
Notes	Please contact Warde Client Services for a	allocated sampl	e volume for your Laboratory.			
Specimen Requiren	nents					
Specimen Required	One nasopharyngeal swab sent frozen in v	iral transport m	edia.			
Alternate Specimen	One oropharyngeal swab or NP/OP sent frozen in viral transport media. Nasal swab sent frozen in viral transport media. Our internal studies show that Phosphate Buffered Saline (PBS) and sterile saline do not interfere with the analytical performance of the COVID-19 assay. Liquid Amies buffer may decrease the analytical sensitivity of the assay and should be used only when other transport media are not available.					
Rejection Criteria	Calcium Alginate swabs, cotton swabs with >72 hours refrigerated	n wood shaft, re	ceived room temperature or			
Stability	Room Temperature: Not Recommended; F	Refrigerated: 72	hours; Frozen: 2 weeks			
Performing Informa	ation					
Methodology	Real-Time Polymer	ase Chain Reactio	on (PCR)			
Reference Range	Not	detected				
Performed Days	Sunday - Saturday					
Turnaround Time	2 - 4 days					
Performing Laboratory	Warde Medical Laboratory					
Interface Informati	on					
Legacy Code ¹		COVW				
Interface Order Code	3000089					
Result Code	Name	LOINC Code	AOE/Prompt ²			
3000091	First Test? (Y/N/U) Acceptable Prompt Responses: Y	95417-2	Yes			

LAST EDITED: 2020-07-22 PAGE 5 OF 8



JULY 22, 2020 IMMEDIATE ACTION

	N U		
3000092	Employed in healthcare? (Y/N/U) Acceptable Prompt Responses: Y N U	95418-0	Yes
3000093	Symptomatic as defined by CDC? (Y/N/U) Acceptable Prompt Responses: Y N U	95419-8	Yes
3000094	if yes, then Date of Symptom Onset mm/dd/yy Acceptable Prompt Responses: If applicable: mm/dd/yy If not applicable: NA or N/A	11368-8	Yes
3000096	Hospitalized? (Y/N/U) Acceptable Prompt Responses: Y N U	77974-4	Yes
3000097	ICU? (Y/N/U) Acceptable Prompt Responses: Y N U	95420-6	Yes
3000098	Resident in a congregate care setting? (Y/N/U) Acceptable Prompt Responses: Y N U	95421-4	Yes
3000099	Pregnant? (Y/N/U) Acceptable Prompt Responses: Y N U	82810-3	Yes
3000066	SARS-CoV-2 Qual RT PCR	94500-6	No

LAST EDITED: 2020-07-22 PAGE 6 OF 8



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

	Molecula	r				
	Collected:	07/14/2020	11:00	Received:	07/15/2020	12:33
<u>Test Name</u>	<u>Result</u>	Flag	Ref-Ranges	<u>. </u>	<u>Jnits</u>	<u>Site</u>
SARS - COV - 2 Qualitative						
First Test? (Y/N/U)	Υ					WMRL
Employed in healthcare? (Y/N/U)	U					WMRL
Symptomatic as defined by CDC? (Y/N/U)	Υ					WMRL
if yes, then Date of Symptom Onset (mm/dd/yy)	07/11/20					WMRL
Hospitalized? (Y/N/U)	U					WMRL
ICU? (Y/N/U)	N					WMRL
Resident in a congregate care setting? (Y/N/U)	N					WMRL
Pregnant? (Y/N/U)	N					WMRL
SARS-CoV-2 Qual RT PCR	DETECTED	AB	Not detected	d		WMRL

This test was performed via the Abbott RealTime SARS-CoV-2 assay and has been authorized by FDA under an Emergency Use Authorization (EUA). The assay is validated for nasopharyngeal (NP) and oropharyngeal (OP) swabs in transport media. The limit of detection of the assay is approximately 100 copies per milliliter; however, detection of SARS-CoV-2 may be affected by the sample collection and transport methods, patient factors (e.g., presence of symptoms, and/or stage of infection), and a negative result does not rule out the possibility of infection. For updated information, refer to the Center for Disease Control website: www.cdc.gov/coronavirus.

Providers should also refer to the fact sheet available at the following link: http://www.wardelab.com/Abbott_COVID_test_fact_sheet_for_

http://www.wardelab.com/Abbott_COVID_test_fact_sheet_for_providers.pdf

Patients should also refer to the fact sheet available at the following link: http://www.wardelab.com/Abbott_COVID_test_fact_sheet_for_patients.pdf

Performing Site:

WMRL: WARDE MEDICAL LABORATORY 300 West Textile Road Ann Arbor MI 48108



JULY 22, 2020 IMMEDIATE ACTION

Inactivate Test	Inactivate Test With Replacement					
Effective Date	7/	28/2020				
	Inactivated Tes	it				
Name		kel, Urine				
Code		NICKU				
Legacy Code ¹		NICKU				
Interface Order Code	3	600080				
Notes						
	Replacement Te	est				
Name	Nic	kel, Urine				
Code		NICRU				
CPT Code(s)	83885					
Notes						
Specimen Requirer	nents					
Specimen Required	non-essential over the counter medication. Abstinence from iodine - containing medications or contrast agents for at least 1 month prior to urine collection is recommended. Collect 24 hour urine, refrigerate during collection. Send 8.0 mL urine (1.0 mL minimum) refrigerated in a blue-capped ARUP metal-free screw-capped plastic vial. Record total volume and collection time interval on container.					
Alternate Specimen	Urine, random					
Rejection Criteria	Acid preserved urine, specimens contamin collected within 24 hours of gadolinium ad					
Stability	Room temperature: 7 days; Refrigerated: 2	l4 days; Frozen:	1 year			
Performing Information	ation					
Methodology	Quantitative Inductively Cou	ıpled Plasma - M	ass Spectrometry			
Reference Range	Ву	report				
Performed Days	Sunday-Saturday	· ·				
Turnaround Time	3 - 11 days					
Performing Laboratory	ARUP Refe	rence Laboratory				
Interface Informati	on					
Legacy Code ¹		NICRU				
Interface Order Code	3600183					
Result Code	Name					
3600184	Hours collected	30211-7	Yes			

LAST EDITED: 2020-07-22 PAGE 7 OF 8



JULY 22, 2020 IMMEDIATE ACTION

3600185	Total Volume	19153-6	Yes
3600186	Creatinine, Urine - per volume	2161-8	No
3600187	Creatinine, Urine - per 24h	2162-6	No
3600188	Nickel, Urine - per volume	14099-6	No
3600189	Nickel, Urine - per 24h	5705-9	No
3600191	Nickel, Urine - ratio to CRT	29936-2	No

Inactivate Test Without Replacement				
Effective Date	8/3/2020			
Name	Candida Antigen			
Code	CANAG			
Legacy Code	CANAG			
Interface Code	3500590			
Notes				

LAST EDITED: 2020-07-22 PAGE 8 OF 8



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT

WX0000003039 M 12/05/1988 31 Y

Referral Testing											
	Colle	ected: 07/16/2020	16:36	Received:	07/22/2020	16:36					
<u>Test Name</u>	Result	<u>Flag</u>	Ref-Ranges	<u>U</u>	<u>nits</u>	<u>Site</u>					
Nickel, Urine											
Hours collected	6			h	ſ	ARRL					
Total Volume	500			m	ıL	ARRL					
Creatinine, Urine - per volume	76			m	ıg/dL	ARRL					
Creatinine, Urine - per 24h	1520		1000-2500	m	ıg/d	ARRL					
Nickel, Urine - per volume	11.0	Н	0.0-10.4	u	a/L	ARRL					

TEST INFORMATION: Nickel, Urine

Measurement of nickel is not recommended in asymptomatic individuals or in individuals with a low likelihood of exposure. Elevations in nickel urine should be interpreted with caution in individuals with no exposure risks, and may indicate contamination of the specimen.

Test developed and characteristics determined by ARUP Laboratories. See Compliance Statement B: aruplab.com/CS

 Nickel, Urine - per 24h
 22.0
 H
 0.0-14.9
 ug/d
 ARRL

 Nickel, Urine - ratio to CRT
 14.5
 H
 0.0-9.9
 ug/g CRT
 ARRL

Performed by ARUP Laboratories, 500 Chipeta Way, SLC,UT 84108 800-522-2787 www.aruplab.com, Julio Delgado, MD - Lab. Director

Performing Site:

ARRL: ARUP REFERENCE LAB 500 Chipeta Way Salt Lake City UT 841081221

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

B522000012 WX0000003039 Printed D&T: 07/22/20 16:44 Ordered By: CLIENT CLIENT WX000000000001595